EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 12
Issue: 1
Year: 2025

EMPOWERING TOMORROW'S PHARMACISTS: TACKLING ELEPHANTIASIS THROUGH EDUCATION

Sughosh V. Upasani[*1], Pankaj G. Jain[2], Uday L. Bachhav[3], Govinda S. Bhandari[4], Vaibhav S. Mahajan[3] and Sayyed Rehan Sayyed Nabi[3]

[1]Department of Pharmacy Practice, SES's R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, 425405, Dhule, Maharashtra, India.
[2]Department of Pharmacology, SES's R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, 425405, Dhule, Maharashtra, India.
[3]Department of Pharmaceuticals Quality Assurance, KVPS's Institute of Pharmaceutical Education, Boradi, Dhule, Maharashtra, India.
[4]Department of Pharmaceutics, SES's R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, 425405, Dhule, Maharashtra, India.

***Corresponding Author: Sughosh V. Upasani**
Department of Pharmacy Practice, SES's R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, 425405, Dhule, Maharashtra, India.

Article Received on 15/11/2024 **Article Revised on 04/12/2024** **Article Accepted on 25/12/2024**

ABSTRACT

Introduction: Elephantiasis, primarily caused by lymphatic filariasis, is a debilitating disease affecting millions globally, with significant physical, psychosocial, and economic burdens. Awareness programs are critical in preventing and managing the disease effectively. **Materials and Methods:** A questionnaire assessing awareness about elephantiasis was administered to 190 pharmacy students before and after awareness sessions conducted in July and August 2024. The program included lectures and discussions focused on prevention, early detection, and management. Data collected was analysed using Microsoft Excel to identify knowledge gaps and evaluate program impact. **Results and Discussion:** The pre-program analysis revealed a lack of awareness regarding preventive measures and management strategies. Post-program data showed a marked improvement in participants' understanding, emphasizing the effectiveness of targeted awareness campaigns. Visual comparisons highlighted significant changes in knowledge levels among students, showcasing the role of education in bridging awareness gaps. **Conclusion:** Awareness programs significantly enhance understanding of elephantiasis prevention and management. Pharmacy students, as future healthcare providers, can play a pivotal role in promoting public health initiatives and addressing neglected tropical diseases like elephantiasis.

KEYWORDS: Elephantiasis, Lymphatic Filariasis, Awareness Programs, Pharmacy Students, Preventive Healthcare, Neglected Tropical Diseases.

INTRODUCTION

The earliest records of elephantiasis date back to ancient Egypt, where swollen limbs depicted in art and texts. The Ebers Papyrus (c. 1550 BCE) described conditions resembling elephantiasis, emphasizing the severity of leg swelling (Raju, 2000). Similarly, Hindu texts like the Sushruta Samhita (circa 600 BCE) mentioned diseases involving gross swelling, which might include elephantiasis (Chandra, 2010). Ancient Greek physicians, including Hippocrates (460–377 BCE), documented cases of what might have been elephantiasis, noting its debilitating effects on mobility and quality of life (Engelkirk & Duben-Engelkirk, 2011). The Roman writer Aulus Cornelius Celsus (25 BCE–50 CE) also described lymphatic swelling in his medical treatises, suggesting early recognition of the disease's physiological impact. During the Middle Ages, elephantiasis was often confused with leprosy due to the similarity in skin changes. This misidentification led to significant social stigma, as individuals with elephantiasis ostracized (Ziegler, 2003). The identification of lymphatic filariasis as a cause of elephantiasis began in the 17th century when Dutch microscopist Antonie van Leeuwenhoek first observed parasites under the microscope (Laird, 1983). In 1866, Timothy Lewis identified Wuchereria bancrofti, linking the parasitic nematode to the disease (Beaver et al., 1984). Around the same time, Patrick Manson demonstrated the role of mosquitoes in transmitting filariasis, cementing the understanding of its etiology (Manson, 1878). Advances in medicine in the 20th century led to the development of anti-filarial drugs and

mass drug administration programs to combat lymphatic filariasis, significantly reducing the prevalence of elephantiasis in endemic regions (Ottesen et al., 1997). By 2018, the number of infected individuals had declined to 51 million, representing a 74% reduction since the launch of the WHO's Global Programme to Eliminate Lymphatic Filariasis in 2000. A comprehensive care package is available to relieve suffering and prevent further disability for individuals affected by lymphatic filariasis. Twenty-one countries and territories, including Bangladesh, Brazil, Sri Lanka, Thailand, and Yemen, have recognized for eliminating lymphatic filariasis as a public health problem. (WHO 2023).

Definition and Characterization

Elephantiasis, also known as lymphatic filariasis, is a debilitating and disfiguring disease primarily caused by infection with filarial nematodes such as Wuchereria bancrofti, Brugia malayi, and Brugia timori. Lymphatic filariasis disrupts the lymphatic system, leading to abnormal body part enlargement, pain, severe disability, and social stigma. It is classified as a neglected tropical disease (NTD) by the World Health Organization (WHO) due to its significant impact on impoverished communities, particularly in tropical and subtropical regions. Over 657 million people in 39 countries remain at risk of lymphatic filariasis and require preventive chemotherapy to curb this parasitic infection. The disease can be eradicated by halting its spread through annual preventive chemotherapy with safe medicine combinations. Since 2000, more than 9.7 billion treatments have been administered to combat the infection. (WHO, 2022). Characterized by severe swelling of the limbs, breasts, or genitalia, the condition results from chronic inflammation and obstruction of the lymphatic system (Taylor et al., 2018). The disease has a long historical presence, with descriptions found in ancient medical texts and reports from endemic regions. Today, over 120 million people in more than 70 countries are affected, with approximately 40 million suffering from severe forms of the disease (Debrah et al., 2017). The condition not only imposes physical and psychological burdens on patients but also contributes to economic hardship by reducing productivity and increasing healthcare costs. Efforts to combat elephantiasis include vector control, mass drug administration (MDA), and public health campaigns aimed at education and prevention. Despite these initiatives, challenges such as reinfection and limited resources hinder eradication efforts (WHO, 2023).

Etiology and Pathogenesis

Elephantiasis, primarily caused by lymphatic filariasis, results from infection with parasitic filarial worms such as Wuchereria bancrofti, Brugia malayi, and Brugia timori. These parasites were transmitted to humans through the bites of infected mosquitoes, including species of Culex, Anopheles, and Aedes (Taylor et al., 2018). During the blood meal, infective larvae (L3 stage) enter the human host and mature into adult worms in the lymphatic system. The adult worms release microfilariae, which circulate in the bloodstream and perpetuate the infection cycle when taken up by another mosquito (Bockarie et al., 2020). The pathogenesis of elephantiasis involves chronic inflammation and immune responses to the presence of adult worms and microfilariae. The obstruction and damage to lymphatic vessels lead to lymphatic dysfunction, causing fluid accumulation (lymphedema) and subsequent tissue thickening. Persistent inflammation results in fibrosis and skin changes, characteristic of advanced disease stages (Debrah et al., 2017). Nonfilarial causes, such as podoconiosis, involve lymphatic damage due to prolonged exposure to irritant soils. The disease progresses through acute episodes of fever and lymphangitis to chronic manifestations of severe lymphedema and gross limb enlargement. These pathological changes often create significant physical disability and psychological burden, particularly in endemic regions with inadequate healthcare access (WHO, 2023).

Clinical Manifestations

Elephantiasis, primarily caused by lymphatic filariasis, manifests in acute and chronic stages with varying symptoms. In the acute stage, patients often experience episodic fever, lymphangitis, and lymphadenitis, accompanied by localized swelling in the affected limbs **(Figure no 01)**. These symptoms arise from inflammatory responses triggered by the death of adult filarial worms or microfilariae, leading to temporary lymphatic obstruction (Taylor et al., 2018). In the chronic stage, progressive lymphedema develops due to long term lymphatic dysfunction and fibrosis. This condition is characterized by gross swelling and hardening of the skin and subcutaneous tissues, in the lower limbs, arms, breasts, or genitalia. The skin becomes thickened and coarse, resembling elephant skin, hence the term "elephantiasis" (Debrah et al., 2017). Secondary bacterial infections, such as cellulitis or erysipelas, exacerbate the condition and increase the risk of further complications (Bockarie et al., 2020). The disease also has significant psychosocial implications. The disfigurement, restricted mobility, and societal stigma lead to emotional distress, depression, and a reduced quality of life for patients, particularly in low resource settings (Gyapong et al., 2018). Addressing these manifestations requires early diagnosis and comprehensive management strategies to prevent progression and mitigate complications. Lymphedema: Persistent swelling due to impaired lymphatic drainage. Elephantiasis: Advanced stages involve extensive tissue swelling and skin thickening. Hydrocele: Common in male patients, involving fluid accumulation in the scrotum. Episodic Adenolymphangitis: Painful, acute inflammation of lymph nodes and vessels. Dermato-lymphangio-adenitis: Recurrent bacterial infections leading to skin damage and worsening lymphedema.

Figure 01 - Elephantiasis of the leg.
(Image courtesy by Dr. Steven A. Williams, AND National Museum of Health and Medicine, Via Wikimedia Commons).

Diagnosis of Elephantiasis

The diagnosis of elephantiasis involves clinical evaluation, laboratory investigations, and imaging techniques to confirm the underlying cause. A thorough clinical examination focuses on identifying characteristic symptoms such as swelling, skin thickening, and lymphatic dysfunction. The presence of acute lymphangitis or chronic lymphedema may suggest filarial infection or alternative causes like podoconiosis (Bockarie et al., 2020). Laboratory tests play a crucial role in confirming the parasitic etiology. Microscopic examination of blood samples for microfilariae remains a gold standard, particularly with nocturnal blood collection due to the parasite's periodicity. Antigen detection assays, such as immunochromatographic tests, offer rapid and sensitive results, while molecular diagnostics like polymerase chain reaction (PCR) enable species specific identification (Debrah et al., 2017). Imaging techniques such as ultrasonography are invaluable in assessing lymphatic vessel abnormalities. Ultrasonography can detect adult filarial worms, often referred to as the "filarial dance sign," within lymphatic channels (Taylor et al., 2018). These methods help differentiate filarial elephantiasis from conditions with similar presentations, such as chronic venous insufficiency or lipedema. A comprehensive approach that combines clinical and diagnostic tools is critical for accurate diagnosis and effective management of elephantiasis.

Management and Treatment of Elephantiasis

Effective management of elephantiasis involves a combination of pharmacological treatments, surgical interventions, and supportive care. Antifilarial medications, such as diethylcarbamazine (DEC), ivermectin, and albendazole, are cornerstone therapies aimed at reducing microfilarial load and preventing disease progression (WHO, 2023). The combination of albendazole and ivermectin is particularly effective in mass drug administration (MDA) programs for endemic regions (Taylor et al., 2018). For secondary infections, antibiotics are essential to combat bacterial cellulitis, a frequent complication due to compromised skin integrity (Debrah et al., 2017). In cases of severe lymphedema, surgical interventions like lymphatic bypass or tissue excision may be performed to reduce the bulk of affected limbs and improve functionality (Bockarie et al., 2020). Lymphedema management focuses on hygiene, skin care, and reduction of swelling through physical therapy and compression garments. These measures also lower the risk of recurrent infections. Manual lymphatic drainage, an advanced massage technique, may help alleviate symptoms (Ramaiah et al., 2021). Patient education on selfcare practices plays a critical role in improving quality of life. Comprehensive treatment strategies must address both physical and psychosocial impacts of the disease to ensure holistic care (WHO, 2023).

Prevention and Control of Elephantiasis

Preventing elephantiasis requires integrated measures targeting the filarial parasite and its mosquito vectors. Vector control is a cornerstone of prevention, involving the use of insecticide treated nets (ITNs) and indoor residual spraying to reduce mosquito populations. Larvicidal treatments in stagnant water sources can help curb breeding grounds for vector mosquitoes (Culex, Anopheles, and Aedes species) (Taylor et al., 2018). Mass Drug Administration (MDA) programs have been pivotal in reducing transmission. Anti-filarial drugs such

as diethylcarbamazine (DEC), ivermectin, and albendazole are distributed to entire communities in endemic regions to suppress microfilariae in the blood, minimizing the risk of infection to mosquitoes (WHO, 2022). These programs require consistent community engagement and health infrastructure support to ensure high coverage rates. Health education is essential for prevention, focusing on personal hygiene and the importance of participating in MDA campaigns. Proper hygiene and skin care can also help manage lymphedema and prevent secondary infections in at risk populations (Molyneux et al., 2021). Sustained efforts, combining vector control, MDA, and community education, have shown significant success in regions like Southeast Asia and Africa, highlighting the potential for eliminating lymphatic filariasis as a public health problem (Gyapong et al., 2018).

Public Health Impact of Elephantiasis

Elephantiasis imposes a substantial burden on public health, especially in endemic regions across Asia, Africa, and the Americas. Approximately 120 million people are infected globally, with over 40 million experiencing severe disability due to lymphedema and hydrocele (WHO, 2023). This disease significantly affects individuals' quality of life, leading to physical disabilities and profound social stigma, often resulting in economic hardships due to lost productivity and healthcare costs (Gyapong et al., 2018). The economic burden is particularly pronounced in low income countries where healthcare resources are limited. Individuals with advanced symptoms often require lifelong care, further straining families and communities (Molyneux et al., 2021). Psychological impacts, including anxiety and depression, are also prevalent due to the visible disfigurement and associated societal exclusion (Debrah et al., 2017). Global initiatives like the WHO's Global Program to Eliminate Lymphatic Filariasis (GPELF) aim to reduce this burden by promoting mass drug administration (MDA) programs and vector control strategies (Bockarie et al., 2020). Collaborative efforts between governments, NGOs, and research institutions have successfully decreased the prevalence in many regions, demonstrating the importance of sustained intervention for eliminating the public health impact of elephantiasis (WHO, 2023).

Recent Advances in Research on Elephantiasis

Significant progress has been made in the research and understanding of elephantiasis, particularly in the areas of vaccines, genomics, and diagnostic tools. The development of antifilarial vaccines is a promising avenue. Efforts to create vaccines targeting the larval stage of filarial worms are ongoing, with early trials showing potential for disrupting the parasite's lifecycle. These vaccines aim to complement existing mass drug administration (MDA) programs, addressing gaps in treatment coverage. Genomic studies have provided critical insights into the biology of Wuchereria bancrofti and other filarial parasites. Whole genome sequencing has identified potential drug targets and genetic markers for resistance, paving the way for more effective therapeutics. Additionally, these studies enhance our understanding of parasite host interactions, informing novel intervention strategies. Innovative diagnostic tools are improving the accuracy and speed of elephantiasis detection. Molecular diagnostics, such as polymerase chain reaction (PCR)based assays, offer higher sensitivity in identifying microfilariae, even in low prevalence settings. Ultrasonography advances, particularly "filarial dance sign" imaging, are aiding in non-invasive detection of adult worms in lymphatic vessels. These advancements collectively support global eradication efforts, promising improved disease management and reduced transmission. Case studies from regions with high endemic rates of elephantiasis provide valuable insights into the success and challenges of treatment and prevention programs. For example, in India, the National Filaria Control Program (NFCP) has seen significant progress in reducing the prevalence of lymphatic filariasis. A study conducted in the state of Karnataka showed that mass drug administration (MDA) programs, which distribute antifilarial drugs like diethylcarbamazine (DEC) and albendazole, have reduced microfilarial prevalence by over 60% in endemic areas. However, challenges such as irregular drug coverage and resistance to treatment still persist, particularly in rural and underserved populations (Ramaiah et al., 2021). Similarly, in Tanzania, the Carter Center has been working with local health authorities to eliminate lymphatic filariasis. A successful case in Pemba Island demonstrated a sharp reduction in cases through comprehensive vector control measures combined with MDA campaigns. Regular monitoring and community engagement were key to overcoming local resistance to the program. Despite these successes, challenges remain in achieving global elimination targets, primarily due to logistical issues, continued lack of awareness, and socioeconomic barriers in endemic regions (Kulkarni et al., 2019).

MATERIALS AND METHODS

A questionnaire was prepared before and after conducting the awareness programs, and participants were asked to complete it. A convenience-based sampling methodology was selected for the study. To assess respondents' levels of awareness about elephantiasis, this survey included questions about various factors associated with the disease. The investigation was carried out during July and August 2024. Students were asked to use all resources to gather information on these questions before awareness program. Same things were discussed along with other important information in various sessions. Microsoft Excel was used for all data management and statistical analysis. Subsequently, a thorough examination of the data revealed specific areas where respondents' answers were inaccurate, prompting a focused emphasis on those aspects. A series of lectures, and an awareness campaign were conducted for students. After completing the

awareness program, the same questionnaire was distributed again for participants to fill out.

Questionnaire with answers

1. What is the primary cause of elephantiasis? Filarial worm infection
2. Which filarial worm is most commonly associated with elephantiasis? Wuchereria bancrofti
3. What is the primary vector for the transmission of elephantiasis? Mosquito
4. What is the most common symptom during the acute phase of elephantiasis? Fever and swelling
5. Which diagnostic test is used to detect microfilariae in the blood? Blood smear
6. Which of the following treatments used to treat elephantiasis caused by filarial worms? Diethylcarbamazine (DEC)
7. What is the role of mass drug administration (MDA) in the prevention of elephantiasis? Administers antifilarial drugs to entire communities
8. Which mosquito species is primarily responsible for transmitting the filarial worms? Aedes, Culex, Anopheles
9. Which of the following is a complication of elephantiasis? Secondary infections
10. Which part of the body is most commonly affected by elephantiasis? Limbs and genitalia
11. What type of inflammation occurs during the acute phase of elephantiasis? Lymphangitis
12. Which of the following used for skin care in the management of elephantiasis? Proper hygiene and moisturization
13. Which is the surgical interventions may be used in severe cases of elephantiasis? Lymphatic bypass
14. What is the primary focus of vector control in preventing elephantiasis? Insecticide spraying and mosquito nets
15. Which is a goal of WHO's Global Program to eliminate Lymphatic Filariasis? Complete eradication of elephantiasis
16. Which of the following is a major barrier to elephantiasis eradication in endemic regions? Stigma associated with the disease
17. Which of the following methods used to control mosquito populations? Indoor residual spraying of insecticides
18. Which of the following countries NOT typically affected by elephantiasis? Canada
19. Which of the following is an effective method for reducing elephantiasis stigma? Health education and community awareness
20. What type of filarial worm is associated with elephantiasis in Asia? Brugia malayi
21. Which condition is NOT a risk factor for developing elephantiasis? Regular use of mosquito nets
22. What is the main focus of elephantiasis management in the chronic stage? Lymphedema management and prevention of infections
23. Which of the following drugs NOT used for the treatment of elephantiasis? Paracetamol
24. What is the most commonly affected area in the body in elephantiasis? Genitalia and legs
25. Which global health organization is leading the efforts to eliminate elephantiasis? World Health Organization (WHO)
26. What is the function of mass drug administration (MDA) programs? To provides antifilarial drugs to entire communities
27. Which of the following is a typical complication of elephantiasis in the long term? Severe skin infections
28. Which mosquito species is commonly involved in transmitting Wuchereria bancrofti? Culex
29. Which of the following is a nonfilarial cause of elephantiasis? Podoconiosis

RESULTS AND DISCUSSION

In a recent study, we discovered that a significant number of individuals lacked awareness of the recommended methods for preventing and managing elephantiasis. This finding is particularly concerning given that elephantiasis, caused primarily by lymphatic filariasis, is a debilitating condition that significantly impacts the quality of life. Early detection and preventive measures, such as proper hygiene and timely treatment of infections, can play a crucial role in reducing its prevalence and severity. The gap in knowledge highlights the urgent need for initiatives aimed at raising awareness about elephantiasis prevention and management. To effectively address this issue, it is essential to establish comprehensive awareness programs that not only educate individuals but also involve the broader community. These initiatives should include community events, expert-led lectures, and discussions that provide accurate information and encourage proactive health behaviors. The study involved a total of 190 pharmacy students who participated in a breast cancer awareness event. Among the participants, the gender distribution was nearly balanced, with 47.45% being males and 52.55% being females. **Table No. 01**, which offers a thorough summary of the population characteristics, contains the demographic information of these participants in great detail.

Table No. 01: Socioeconomic and demographic factors.

Particulars		Female		Male		Total	
		Number	%	Number	%	Number	%
Age in Years	16– 19	82	30.37	70	25.93	152	56.30
	20– 22	58	21.48	58	21.48	116	42.96
	Other	2	0.74	0	0.00	2	0.74
Type of Family	Nuclear	80	29.63	24	8.89	104	38.52
	Joint	52	19.26	42	15.56	94	34.81
	Extended	8	2.96	12	4.44	20	7.41
	Other	0	0.00	2	0.74	2	0.74
Current Location (Residence)	Urban	18	6.67	34	12.59	52	19.26
	Rural	112	41.48	88	32.59	200	74.07
	Metro city	4	1.48	4	1.48	8	2.96
	Other	6	2.22	2	0.74	8	2.96
Socio economic factor (Family gross income)	20 K - 50 K	66	24.44	88	32.59	154	57.04
	51 K - 70 K	24	8.89	14	5.19	38	14.07
	71 K - 100 K	8	2.96	2	0.74	10	3.70
	> 01 Lakh	38	14.07	22	8.15	60	22.22
	> 05 Lakh	4	1.48	10	3.70	14	5.19
	> 10 Lakh	0	0.00	0	0.00	0	0.00
Body Mass Index	Underweight	28	10.37	22	8.15	50	18.52
	Normal	106	39.26	98	36.30	204	75.56
	Overweight	2	0.74	8	2.96	10	3.70
	Obese	2	0.74	2	0.74	4	1.48
	Don't know	2	0.74	0	0.00	2	0.74

The data gathered before and after the implementation of the awareness programs is depicted graphically in the illustrations that follow in **Figure no 02** and **Figure no 03**. The figures are self-explanatory. These illustrations offer a visual representation of the changes in awareness and understanding among the participants, highlighting the positive impact of the awareness programs. The study underscores the importance of targeted health education initiatives, especially in regions and populations where awareness levels are low, and it provides valuable insights into the factors that influence health awareness and education outcomes.



Figure 02 – Responses for questionnaire about Elephantiasis, before awareness program.



	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17	Q18	Q19	Q20	Q21	Q22	Q23	Q24	Q25	Q26	Q27	Q28	Q29
%	94	94	98	92	94	93	87	79	86	79	88	84	89	81	92	82	80	95	80	94	89	85	82	86	92	96	97	85	87
%	6	6	2	8	6	7	13	21	14	21	12	16	11	19	8	18	20	5	20	6	11	15	18	14	8	4	3	15	13

Figure 02 – Responses for questionnaire about Elephantiasis, after awareness program.

Our research underscores the critical role that pharmacy students and healthcare professionals can play in these efforts. As future healthcare providers, pharmacy students are in a unique position to influence public health positively. By participating in awareness activities, they can help bridge the knowledge gap and promote preventive practices among the population. Teachers, in particular, have a significant responsibility in this context. They are instrumental in shaping the knowledge and attitudes of students toward health issues. By integrating elephantiasis awareness into the educational curriculum and encouraging active participation in awareness programs, teachers can foster a culture of health consciousness among future healthcare professionals. This approach not only benefits the individual students but also contributes to the collective good of society by empowering them to become advocates for elephantiasis prevention and management in their communities.

CONCLUSION

Elephantiasis, caused primarily by filarial infections, continues to pose a significant public health challenge, particularly in tropical and subtropical regions. Despite decades of efforts to control and eliminate the disease, it remains endemic in many countries, causing both physical and psychosocial burdens. The management of elephantiasis relies on a combination of antifilarial drugs, surgical interventions, and lymphedema management strategies. Global programs like the WHO's Global Program to Eliminate Lymphatic Filariasis (GPELF) have made substantial progress, yet challenges in disease transmission, access to healthcare, and stigma persist (WHO, 2023). Future directions in tackling elephantiasis involve continued innovation in research and treatment strategies. Vaccine development remains a key focus, with promising trials underway to provide more effective and long lasting protection against filarial infections (Ramaiah et al., 2021). Moreover, advances in molecular diagnostics offer new tools for early detection, allowing for more targeted and efficient treatment approaches (Bockarie et al., 2020). Continued emphasis on mass drug administration (MDA) programs, vector control, and public education will be crucial in eliminating the disease. With sustained efforts, improved technologies, and enhanced community engagement, the global goal of eradicating elephantiasis can be achieved, reducing both its physical impact and the stigma associated with it (Molyneux et al., 2021).

ACKNOWLEDGMENT

Authors are thankful to Principal, R. C. Patel Institute of Pharmaceutical Education & Research, Principal, R. C. Patel Institute of Pharmacy, Shirpur-425405, and Principal, Institute of Pharmaceutical Education, Boradi, Dhule, Maharashtra, India for providing facilities to carry out this research.

CONFLICT OF INTEREST – None declared.

SOURCE OF FUNDING – Nil.

REFERENCES

1. Beaver, P. C., Jung, R. C., & Cupp, E. W. (1984). Clinical Parasitology. Lea & Febiger.
2. Bockarie, M. J., et al. (2013). "Impact of mass drug administration on lymphatic filariasis in Africa: A review of the evidence." Parasitology, 140(7): 933939. doi: 10.1017/S0031182013000169.
3. Bockarie, M. J., et al. (2020). "Lymphatic filariasis: Epidemiology, diagnosis, and management." Clinical Infectious Diseases, 70(1): 5–11. doi: 10.1093/cid/ciy475.
4. Bockarie, M. J., Taylor, M. J., & Gyapong, J. O. (2020). Lymphatic filariasis: Current status and future challenges. Tropical Medicine & International Health, 25(3): 227–233.
5. Chakraborty, S., Gurusamy, M., Zawieja, D. C., & Muthuchamy, M. (2013). Lymphatic filariasis: Perspectives on lymphatic remodelling and

contractile dysfunction in filarial disease pathogenesis. Microcirculation, 20(5): 349–364. DOI:10.1111/micc.12031.
6. Chandra, R. (2010). History of Medicine in India: From Antiquity to 21st Century. NBT India.
7. Debrah, A. Y., et al. (2017). Diagnostic challenges in lymphatic filariasis. Parasite Immunology.
8. Engelkirk, P. G., & Duben-Engelkirk, J. L. (2011). Burton's Microbiology for the Health Sciences. Lippincott Williams & Wilkins.
9. Kulkarni, P., Dowerah, J., Thomas, J., Murthy, M. N., & Ravikumar, K. (2019). Exploring effectiveness of mass drug administration program against lymphatic filariasis in Raichur district, Karnataka. International Journal of Health & Allied Sciences, 8(4): 268.
10. Laird, M. (1983). Antonie van Leeuwenhoek: First Microscopist and First Protozoologist. Springer.
11. Manson, P. (1878). "On the Development of Filaria Sanguinis Hominis, and on Mosquitoes Considered as a Nurse." Journal of the Linnean Society of London, Zoology, 14: 304–311.
12. *Molyneux, D. H., et al. (2021). "Global health initiatives and lymphatic filariasis: Progress, challenges, and prospects." The Lancet Global Health, 9(3): e311–e319. doi: 10.1016/S2214109X(20)305297*.
13. Ottesen, E. A., Duke, B. O. L., Karam, M., & Behbehani, K. (1997). "Strategies and Tools for the Control/Elimination of Lymphatic Filariasis." Bulletin of the World Health Organization, 75(6): 491–503.
14. Raju, T. N. K. (2000). "The Nobel Chronicles: 1902: Ronald Ross (1857–1932)." The Lancet, 355(9217): 1020.
15. Ramaiah, K. D., et al. (2021). "Recent advances in lymphatic filariasis vaccine development." Tropical Medicine and International Health, 26(9): 10961109. doi:10.1111/tmi.13543.
16. Taylor, M. J., et al. (2018). Advances in the diagnosis of lymphatic filariasis. Lancet Global Health.
17. World Health Organization (WHO). (2022). Lymphatic filariasis: Global Program to Eliminate Lymphatic Filariasis. Available at WHO website.
18. World Health Organization (WHO). (2023). Global Programme to Eliminate Lymphatic Filariasis. World Health Organization.
19. World Health Organization (WHO). (2023). Lymphatic filariasis fact sheet.
20. World Health Organization (WHO). (2023). Lymphatic filariasis: Managing morbidity and preventing disability. Geneva: WHO Press.
21. Ziegler, J. (2003). Healing Traditions: Alternative Medicine and the Health Professions. Wiley.